Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05394259 | A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | PHASE1 | RECRUITING | 36 | — | — | Oct 28, 2022 | Feb 2, 2027 | Apr 15, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Piflufolastat F18 | EXPERIMENTAL | Piflufolastat F18 will first be given by vein over about 5 seconds. |
| Name | Type | Description |
|---|---|---|
| Piflufolastat F18 | DRUG | Given by vein (IV) |
Inclusion Criteria: 1. Age ≥18 years. Because no dosing or adverse event data are currently available on the use of PYLARIFY in patients \<18 years of age, children are excluded from this study. 2. ECOG performance status ≤2 (Karnofsky ≥60%,). 3. Subject or subject's Legally Authorized Representati...